Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat

Suresh Varma Penumathsa, Mahesh Thirunavukkarasu, Srikanth Koneru, B. Juhász, Lijun Zhan, Rima Pant, Venugopal P. Menon, Hajime Otani, Nilanjana Maulik

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Hypercholesterolemia (HC) is a common health problem that significantly increases risk of cardiovascular disease. Both statin (S) and resveratrol (R) demonstrated cardioprotection through nitric oxide-dependent mechanism. Therefore, the present study was undertaken to determine whether combination therapy with statin and resveratrol is more cardioprotective than individual treatment groups in ischemic rat heart model. The rats were fed with 2% high cholesterol diet and after 8 weeks of high cholesterol diet the animals were treated with statin (1 mg/kg bw/day) and resveratrol (20 mg/kg bw/day) for 2 weeks. The rats were assigned to: (1) Control (C), (2) HC, (3) HCR, (4) HCS and (5) HCRS. The hearts, subjected to 30-min global ischemia followed by 120-min reperfusion were used as experimental model. The left ventricular functional recovery (+ dp/dtmax) was found to be significantly better in the HCRS (1926 ± 43), HCR (1556 ± 65) and HCS (1635 ± 40) compared to HC group (1127 ± 16). The infarct sizes in the HCRS, HCS and HCR groups were 37 ± 3.6, 43 ± 3.3 and 44 ± 4.2 respectively compared to 53 ± 4.6 in HC. The lipid level was found to be decreased in all the treatment groups when compared to HC more significantly in HCS and HCRS groups when compared to HCR. Increased phosphorylation of Akt and eNOS was also observed in all the treatment groups resulting in decreased extent of cardiomyocyte apoptosis but the extent of reduction in apoptosis was more significant in HCRS group compared to all other groups. In vivo rat myocardial infarction (MI) model subjected to 1 week of permanent left descending coronary artery (LAD) occlusion documented increased capillary density in HCR and HCRS treated group when compared to HCS treatment group. We also documented increased β-catenin translocation and increased VEGF mRNA expression in all treatment groups. Thus, we conclude that the acute as well as chronic protection afforded by combination treatment with statin and resveratrol may be due to pro-angiogenic, anti-hyperlipidemic and anti-apoptotic effects and long-term effects may be caused by increased neo-vascularization of the MI zone leading to less ventricular remodeling.

Original languageEnglish
Pages (from-to)508-516
Number of pages9
JournalJournal of Molecular and Cellular Cardiology
Volume42
Issue number3
DOIs
Publication statusPublished - Mar 2007

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypercholesterolemia
Myocardial Infarction
Cholesterol
Apoptosis
Diet
Catenins
Ventricular Remodeling
Cardiac Myocytes
Vascular Endothelial Growth Factor A
Reperfusion
Coronary Vessels
Nitric Oxide
Theoretical Models
Cardiovascular Diseases
Ischemia
Phosphorylation
resveratrol
Lipids
Messenger RNA

Keywords

  • β-Catenin
  • Akt
  • Cholesterol
  • eNOS
  • Myocardium
  • Resveratrol
  • Statin
  • VEGF

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. / Penumathsa, Suresh Varma; Thirunavukkarasu, Mahesh; Koneru, Srikanth; Juhász, B.; Zhan, Lijun; Pant, Rima; Menon, Venugopal P.; Otani, Hajime; Maulik, Nilanjana.

In: Journal of Molecular and Cellular Cardiology, Vol. 42, No. 3, 03.2007, p. 508-516.

Research output: Contribution to journalArticle

Penumathsa, Suresh Varma ; Thirunavukkarasu, Mahesh ; Koneru, Srikanth ; Juhász, B. ; Zhan, Lijun ; Pant, Rima ; Menon, Venugopal P. ; Otani, Hajime ; Maulik, Nilanjana. / Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. In: Journal of Molecular and Cellular Cardiology. 2007 ; Vol. 42, No. 3. pp. 508-516.
@article{1bb4e3e179ac448b972dcffca51c069b,
title = "Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat",
abstract = "Hypercholesterolemia (HC) is a common health problem that significantly increases risk of cardiovascular disease. Both statin (S) and resveratrol (R) demonstrated cardioprotection through nitric oxide-dependent mechanism. Therefore, the present study was undertaken to determine whether combination therapy with statin and resveratrol is more cardioprotective than individual treatment groups in ischemic rat heart model. The rats were fed with 2{\%} high cholesterol diet and after 8 weeks of high cholesterol diet the animals were treated with statin (1 mg/kg bw/day) and resveratrol (20 mg/kg bw/day) for 2 weeks. The rats were assigned to: (1) Control (C), (2) HC, (3) HCR, (4) HCS and (5) HCRS. The hearts, subjected to 30-min global ischemia followed by 120-min reperfusion were used as experimental model. The left ventricular functional recovery (+ dp/dtmax) was found to be significantly better in the HCRS (1926 ± 43), HCR (1556 ± 65) and HCS (1635 ± 40) compared to HC group (1127 ± 16). The infarct sizes in the HCRS, HCS and HCR groups were 37 ± 3.6, 43 ± 3.3 and 44 ± 4.2 respectively compared to 53 ± 4.6 in HC. The lipid level was found to be decreased in all the treatment groups when compared to HC more significantly in HCS and HCRS groups when compared to HCR. Increased phosphorylation of Akt and eNOS was also observed in all the treatment groups resulting in decreased extent of cardiomyocyte apoptosis but the extent of reduction in apoptosis was more significant in HCRS group compared to all other groups. In vivo rat myocardial infarction (MI) model subjected to 1 week of permanent left descending coronary artery (LAD) occlusion documented increased capillary density in HCR and HCRS treated group when compared to HCS treatment group. We also documented increased β-catenin translocation and increased VEGF mRNA expression in all treatment groups. Thus, we conclude that the acute as well as chronic protection afforded by combination treatment with statin and resveratrol may be due to pro-angiogenic, anti-hyperlipidemic and anti-apoptotic effects and long-term effects may be caused by increased neo-vascularization of the MI zone leading to less ventricular remodeling.",
keywords = "β-Catenin, Akt, Cholesterol, eNOS, Myocardium, Resveratrol, Statin, VEGF",
author = "Penumathsa, {Suresh Varma} and Mahesh Thirunavukkarasu and Srikanth Koneru and B. Juh{\'a}sz and Lijun Zhan and Rima Pant and Menon, {Venugopal P.} and Hajime Otani and Nilanjana Maulik",
year = "2007",
month = "3",
doi = "10.1016/j.yjmcc.2006.10.018",
language = "English",
volume = "42",
pages = "508--516",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat

AU - Penumathsa, Suresh Varma

AU - Thirunavukkarasu, Mahesh

AU - Koneru, Srikanth

AU - Juhász, B.

AU - Zhan, Lijun

AU - Pant, Rima

AU - Menon, Venugopal P.

AU - Otani, Hajime

AU - Maulik, Nilanjana

PY - 2007/3

Y1 - 2007/3

N2 - Hypercholesterolemia (HC) is a common health problem that significantly increases risk of cardiovascular disease. Both statin (S) and resveratrol (R) demonstrated cardioprotection through nitric oxide-dependent mechanism. Therefore, the present study was undertaken to determine whether combination therapy with statin and resveratrol is more cardioprotective than individual treatment groups in ischemic rat heart model. The rats were fed with 2% high cholesterol diet and after 8 weeks of high cholesterol diet the animals were treated with statin (1 mg/kg bw/day) and resveratrol (20 mg/kg bw/day) for 2 weeks. The rats were assigned to: (1) Control (C), (2) HC, (3) HCR, (4) HCS and (5) HCRS. The hearts, subjected to 30-min global ischemia followed by 120-min reperfusion were used as experimental model. The left ventricular functional recovery (+ dp/dtmax) was found to be significantly better in the HCRS (1926 ± 43), HCR (1556 ± 65) and HCS (1635 ± 40) compared to HC group (1127 ± 16). The infarct sizes in the HCRS, HCS and HCR groups were 37 ± 3.6, 43 ± 3.3 and 44 ± 4.2 respectively compared to 53 ± 4.6 in HC. The lipid level was found to be decreased in all the treatment groups when compared to HC more significantly in HCS and HCRS groups when compared to HCR. Increased phosphorylation of Akt and eNOS was also observed in all the treatment groups resulting in decreased extent of cardiomyocyte apoptosis but the extent of reduction in apoptosis was more significant in HCRS group compared to all other groups. In vivo rat myocardial infarction (MI) model subjected to 1 week of permanent left descending coronary artery (LAD) occlusion documented increased capillary density in HCR and HCRS treated group when compared to HCS treatment group. We also documented increased β-catenin translocation and increased VEGF mRNA expression in all treatment groups. Thus, we conclude that the acute as well as chronic protection afforded by combination treatment with statin and resveratrol may be due to pro-angiogenic, anti-hyperlipidemic and anti-apoptotic effects and long-term effects may be caused by increased neo-vascularization of the MI zone leading to less ventricular remodeling.

AB - Hypercholesterolemia (HC) is a common health problem that significantly increases risk of cardiovascular disease. Both statin (S) and resveratrol (R) demonstrated cardioprotection through nitric oxide-dependent mechanism. Therefore, the present study was undertaken to determine whether combination therapy with statin and resveratrol is more cardioprotective than individual treatment groups in ischemic rat heart model. The rats were fed with 2% high cholesterol diet and after 8 weeks of high cholesterol diet the animals were treated with statin (1 mg/kg bw/day) and resveratrol (20 mg/kg bw/day) for 2 weeks. The rats were assigned to: (1) Control (C), (2) HC, (3) HCR, (4) HCS and (5) HCRS. The hearts, subjected to 30-min global ischemia followed by 120-min reperfusion were used as experimental model. The left ventricular functional recovery (+ dp/dtmax) was found to be significantly better in the HCRS (1926 ± 43), HCR (1556 ± 65) and HCS (1635 ± 40) compared to HC group (1127 ± 16). The infarct sizes in the HCRS, HCS and HCR groups were 37 ± 3.6, 43 ± 3.3 and 44 ± 4.2 respectively compared to 53 ± 4.6 in HC. The lipid level was found to be decreased in all the treatment groups when compared to HC more significantly in HCS and HCRS groups when compared to HCR. Increased phosphorylation of Akt and eNOS was also observed in all the treatment groups resulting in decreased extent of cardiomyocyte apoptosis but the extent of reduction in apoptosis was more significant in HCRS group compared to all other groups. In vivo rat myocardial infarction (MI) model subjected to 1 week of permanent left descending coronary artery (LAD) occlusion documented increased capillary density in HCR and HCRS treated group when compared to HCS treatment group. We also documented increased β-catenin translocation and increased VEGF mRNA expression in all treatment groups. Thus, we conclude that the acute as well as chronic protection afforded by combination treatment with statin and resveratrol may be due to pro-angiogenic, anti-hyperlipidemic and anti-apoptotic effects and long-term effects may be caused by increased neo-vascularization of the MI zone leading to less ventricular remodeling.

KW - β-Catenin

KW - Akt

KW - Cholesterol

KW - eNOS

KW - Myocardium

KW - Resveratrol

KW - Statin

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=33847375577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847375577&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2006.10.018

DO - 10.1016/j.yjmcc.2006.10.018

M3 - Article

C2 - 17188708

AN - SCOPUS:33847375577

VL - 42

SP - 508

EP - 516

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 3

ER -